On December 16th, during the 18th Asia-Pacific Symposium on Hypertension, the National Launching Meeting of Sacubitril Valsartan Sodium Tablets (trade name: Yixintan®), which is exclusively commercialized by Fosun Pharmaceuticals and researched, developed and manufactured by Nanjing Fangshenghe Pharmaceuticals, was held grandly in Shanghai.

The approved indications of Yixintan® (sacubitril valsartan sodium tablets) are for use in adult patients with chronic heart failure (NYHA class II-IV, LVEF ≤ 40%) with reduced ejection fraction, to reduce the risk of cardiovascular death and hospitalization for heart failure; and for the treatment of essential hypertension. The product is a first-line drug for the treatment of heart failure and hypertension with an innovative crystalline form with independent intellectual property rights.

After the launching ceremony, a press conference on the national launching of Yixintan® was held, in which experts appeared and answered questions from the media about the current situation of cardiovascular prevention and treatment, the unmet needs of patients, and the clinical value of Yixintan®. Mr. Yuan Chun, Global Partner of Fosun and CEO of Fosun Pharma's domestic marketing platform, said that since the establishment of Fosun Pharma, it has been focusing on patients and oriented by clinical needs, and has continued to make deep efforts in the core therapeutic areas of oncology, autoimmunity, central nervous system, and chronic diseases (cardiovascular, metabolic, and renal diseases). China has a large number of cardiovascular disease patients, and cardiovascular deaths occupy the first place in the total causes of death of urban and rural residents, so the challenges and pressures of disease prevention and control exist side by side. As a domestic enterprise, we deeply feel the responsibility. Today, the domestic sacubitril valsartan a Xintan® is officially listed on the national market, which allows more heart failure and hypertension patients in China to use and afford this high-quality, high-priced product, which is also the significance of our adherence to innovation-driven, practicing social responsibility.

It is reported that on December 13, 2023, Sacubitril valsartan sodium tablets have been included in the latest version of the National Health Insurance Catalog, which is expected to further reduce the burden of treatment on patients, improve clinical accessibility, add another tool for disease treatment, and escort the national health.

https://mp.weixin.qq.com/s/a8WzeRJwrsRs8BkYDYYn4g